Chinese pharmaceutical company making traditional-Chinese-medicine-derived drugs, notably for kidney disease.
Chinese pharmaceutical company making traditional-Chinese-medicine-derived drugs, notably for kidney disease.
In one line: A niche Chinese TCM-derived nephrology drug maker.
Moat: narrow (brand, IP / patents). Branded, patent-protected TCM formulations in a niche nephrology segment.
Headquarters: Guangzhou, China · Founded: 1998 · Employees: 3,115
Size Consun Pharmaceutical (1681.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.65B, the 455th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$15.87 on 18 Nov 2026.
Performance Over six months the shares gained 7.5%, against -11.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 15.1% over the last twelve months (peer median +6.6%); the operating margin is 35.5% (peer median 12.0%).
Valuation It trades at 9.2× forward earnings against a peer median of 26.3× (cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -28 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 59.7 points above its cost of capital (7.5% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$4.06B | HK$3.71B | HK$3.22B | HK$2.86B | HK$2.72B |
| Revenue growth | — | +15% | +12% | +5% | — |
| Gross profit | HK$3.25B | HK$2.89B | HK$2.43B | HK$2.12B | HK$2.05B |
| EBITDA | HK$1.52B | HK$1.32B | HK$1.11B | HK$933M | HK$903M |
| Net income | HK$1.31B | HK$1.17B | HK$987M | HK$867M | HK$794M |
| Free cash flow | HK$1.73B | HK$1.34B | HK$1.10B | HK$898M | HK$1.08B |
| Capital expenditure | HK$81.1M | HK$74.3M | HK$118M | HK$58.1M | HK$60.0M |
| Total debt | n/a | HK$299M | HK$284M | HK$563M | HK$517M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Consun Pharmaceutical 1681.HK | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% |
| China Resources Pharmaceutical 3320.HK | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1681.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.1% | -3.9% | 9th highest of 21 |
| 6-month return | +7.5% | -11.9% | 4th highest of 20 |
| Distance from 52-week high | -18.6% | -36.7% | 5th highest of 21 |
| Revenue growth (TTM) | +15.1% | +6.6% | 8th highest of 20 |
| Operating margin | 35.5% | 12.0% | 2nd highest of 20 |
| Forward P/E | 9.2× | 26.3× | cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -14.9% | 18.4% | least demanding of 16 |
| Growth delivered (Del g) | +13.5% | +9.2% | 6th highest of 16 |
| Hurdle (Req g minus delivered) | -28.4 pp | +8.6 pp | 2nd least demanding of 16 |
| ROIC minus cost of capital | +59.7 pp | -2.4 pp | highest of 21 |
| EV / EBITDA | 5.9× | 21.4× | cheapest of 8 |
| Net debt / EBITDA | -2.9× | 0.6× | least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |